Opinion

Video

Results of Lp(a) Testing to Modify Risk Assessment and Optimize Treatment

Author(s):

Nihar Desai, MD, MPH,Nathan Wong, PhD

Experts discuss how knowledge of lipoprotein(a) (Lp[a]) levels can empower patients in managing atherosclerotic cardiovascular disease (ASCVD) risk factors, how providers can collaborate with patients on Lp(a) testing and risk management, the potential population-level value of improved ASCVD risk assessment, and how the National Lipid Association’s (NLA) recommendation for one-time Lp(a) testing may benefit health systems.

Video content above is prompted by the following:

  • How might knowledge of Lp(a) levels empower patients in their management of ASCVD risk factors?
  • How might providers partner with their patients with respect to Lp(a) testing and ASCVD risk management?
  • What value might improved ASCVD risk assessment and risk factor management offer on a population level, such as to a health care system?
  • The NLA recommends Lp(a) testing only once in a patient’s lifetime. How, if at all, might this frequency benefit health systems?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
1 expert in this video
4 experts in this video
4 experts in this video
1 expert is featured in this series.
1 expert is featured in this series.
Related Content
Eliquis packaging | Image credit: Semi – stock.adobe.com
July 17th 2025

Direct-to-Patient Apixaban Program Aims to Expand Access, Lower Out-of-Pocket Costs

Hayden E. Klein
Apixaban would still cost patients 9 times more through the Eliquis 360 Support program than with commercial insurance.
Managed Care Cast
May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi
In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Cardiologist listening to patient's heart | Image credit: Space_Cat – stock.adobe.com
June 19th 2025

40% of Patients With Heart Failure Don’t See Cardiologist Annually, Increasing Risk of Death

Hayden E. Klein
Patients who see a cardiologist at least once a year are about 24% less likely to die in the following year.
Managed care cast logo.
May 10th 2022

For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management

On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.
CBD oils and hemp leaves | Image credit: Irina_Evva – stock.adobe.com
May 23rd 2025

CBD-Based Drug Shows No Heart Safety Risks in Patients With CVD or Risk Factors

Hayden E. Klein
A pharmaceutical-grade cannabidiol (CBD) product was shown to be safe in high-risk patients hospitalized with COVID-19, with no increased rate of cardiac side effects compared with placebo.
AJMC
May 16th 2025

Predicting Mortality Risk Using the PREVENT Equation Across Diverse Racial Groups

Ofer Kobo, MD Martin K. Rutter, MD Shivani Misra, PhD Erin D. Michos, MD, MHS Phyo K. Myint, MD Ariel Roguin, MD, PhD Louise Y. Sun, MD Mamas A. Mamas, MD
This study validates the Predicting Risk of CVD Events (PREVENT) score across diverse racial and ethnic populations, highlighting its effectiveness in predicting cardiovascular risk and mortality, regardless of race or ethnicity.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo